Prevalence of Alcoholic Fatty Liver Disease Among Adults in the United States, 2001-2016.
Wong T, Dang K, Ladhani S, Singal AK, Wong RJ.
JAMA. 2019 May 7;321(17):1723-1725. doi: 10.1001/jama.2019.2276.
PMID:31063562
Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARalpha to activate the NF-kappaB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance.
Kong L, Chen J, Ji X, Qin Q, Yang H, Liu D, Li D, Sun M.
J Exp Clin Cancer Res. 2021 Jan 7;40(1):18. doi: 10.1186/s13046-020-01782-w.
PMID:33413501
FNDC3B protects steatosis and ferroptosis via the AMPK pathway in alcoholic fatty liver disease.
You Y, Liu C, Liu T, Tian M, Wu N, Yu Z, Zhao F, Qi J, Zhu Q.
Free Radic Biol Med. 2022 Nov 20;193(Pt 2):808-819. doi: 10.1016/j.freeradbiomed.2022.10.322. Epub 2022 Nov 3.
PMID:36336231
Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
Lang S, Schnabl B.
Cell Host Microbe. 2020 Aug 12;28(2):233-244. doi: 10.1016/j.chom.2020.07.007.
PMID:32791115
Alcoholic and non-alcoholic fatty liver disease: Focus on ceramide.